While antibody therapies that interfere with the IL-23 are firmly established in the therapeutic concept for diseases such as psoriasis, spondylitis ankylosans, or inflammatory intestine illness (75–77), they are yet not established for the treatment of inflammatory CNS diseases. The gene discussed is IL37; the disease is psoriasis.